WEBULL
WebtradeDownload

Is Establishment Labs Holdings (ESTA) Undervalued As New Clinical Data Tests Its Premium?

Simply Wall St · 1d ago

Establishment Labs Holdings (ESTA) just used the 11th World Symposium on Ergonomic Implants in Istanbul to roll out fresh clinical data on its Breast Tissue Preservation approach and minimally invasive platform.

That clinical showcase lands at an interesting moment for Establishment Labs Holdings, with the share price at US$70.24 after a 1-day share price return of 3.69% and a 90-day share price return that has declined 19.46%, while the 1-year total shareholder return of 64.92% signals that investors who stayed the course have been rewarded despite shorter term volatility.

Scan other medical technology stocks aiming for similar procedure-led momentum by checking the curated list of solid balance sheet and fundamentals (23 results).

After a sharp run over the past year but a weaker 90 day patch, Establishment Labs Holdings now asks a simple question of you as a shareholder: Is it worth paying up today or waiting for a cleaner entry point once the numbers are laid out?

Most Popular Narrative: 31% Undervalued

On the most followed view, Establishment Labs Holdings screens as undervalued, with a fair value of $102.44 set against the last close at $70.24. This puts the current debate squarely on whether earnings can grow fast enough to close that gap.

Accelerating surgeon adoption and utilization curve in the U.S., combined with further account additions and growing patient demand (amplified by patient-driven requests and social media engagement), positions the company for continued strong revenue growth and sustainable market share gains in a large, culturally receptive, and increasingly affluent market.

See why 1 investors see Establishment Labs Holdings as 31% undervalued.

Result: Fair Value of $102.44 (UNDERVALUED)

Still, Establishment Labs Holdings faces real pressure if the China rollout lags expectations or if high SG&A and R&D spend keep profitability and cash flow under strain.

Find out about the key risks to this Establishment Labs Holdings narrative.

Another View: Establishment Labs Holdings Through A Sales Lens

The 31% upside case on Establishment Labs Holdings looks different when viewed through a sales-based pricing lens. The stock trades on a P/S ratio of 8.5x, compared with a fair ratio of 5.8x, the US Medical Equipment industry at 2.9x, and peers at 2.3x.

Those gaps suggest investors are already paying a substantial premium for growth and execution. This raises a simple question for you: is that kind of valuation pressure the trade you want to be in if the story encounters a setback?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqCM:ESTA P/S Ratio as at Sep 2026
NasdaqCM:ESTA P/S Ratio as at Sep 2026

Next Steps

Mixed signals around Establishment Labs Holdings can create noise, so move quickly to review the full picture yourself and pressure test the optimistic angles. To see the upbeat factors investors are focusing on, go straight to the 3 key rewards.

Looking for more investment ideas beyond Establishment Labs Holdings?

If the Establishment Labs Holdings story has sharpened your thinking, do not stop here. The strongest edges often come from comparing multiple high quality ideas side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.